n°91

October 2007

Issue Contents
Editorial

Free  Winners and losers

p.178
Testosterone mongering

Marketing Authorisations

Omalizumab (asthma) (new drug)

p.179-182
Too many unknowns for an anti-IgE

Methotrexate (psoriatic arthritis) (new indication)

p.182
Approved at last

Entecavir (chronic hepatitis B) (new drug)

p.183-185
A last resort

Rituximab (rheumatoid arthritis) (new indication)

p.186-188
For a few patients with close monitoring

Infliximab (psoriatic arthritis) (new indication)

p.188
Just another intravenous me-too drug

Free  Rituximab (lymphoma maintenance therapy) (new indication)

p.189
Inadequate follow-up

Testosterone patch (hypoactive sexual desire disorder) (new drug)

p.190-192
Don't use to stimulate women’s sexual desire

INN common stems: -mab

p.192

INN common stems: -glitazone

p.192

Adalimumab (ankylosing spondylitis) (new indication)

p.193
Just another TNF alpha antagonist

Evra° (labelling change)

p.193
Confirmed risks not emphasised in the SPC

Infliximab (ulcerative colitis) (new indication)

p.194
Caution is needed due to long-term risks

Copies and biosimilar products

p.195
Deliberate lack of precision

Deferiprone

p.196
Second-line treatment of iron overload in the absence of a better alternative

Deferasirox

p.196
For iron overload : only a third-line option

Adverse Effects

Cholinesterase inhibitors: tremor and exacerbations of Parkinson's disease

p.197-198

Risk of confusion between plastic ampoules and other unit-dose containers

p.199

Oseltamivir: neuropsychiatric disorders

p.200

Zolpidem: sleep walking and automatic behaviours

p.200

SSI° BCG vaccine: avoidable adverse effects

p.200-201

Metoclopramide: extrapyramidal symptoms in children

p.201

Rituximab: gastrointestinal perforation

p.201

Tianeptine abuse: yet again!

p.201

Aripiprazole: malignant syndrome

p.201

Reviews

Female sexual dissatisfaction

p.202-205
Hormone therapy inappropriate

Ginkgo and Alzheimer's disease

p.205-207
Little or no different from placebo

Long-term asthma therapy

p.208-211
Adapt steroid therapy to severity

Outlook

Free  India: Novartis' failed action

p.212-213

A strong U.S. and EU industry lobby weakened the REACH Regulation

p.214-216

“Risk management plans”: hardly reassuring!

p.216-217

Herbal medicinal products: towards European harmonisation

p.218

Civic responsibility and concrete action

p.220

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe